E

Editas Medicine
D

EDIT

3.14000
USD
-0.11
(-3.38%)
مغلق
حجم التداول
36,371
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
262,858,377
أصول ذات صلة
ALNY
ALNY
1.29
(0.39%)
329.01 USD
B
BEAM
0.760
(3.62%)
21.730 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
N
NTLA
0.830
(6.50%)
13.595 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SRPT
-0.970
(-7.53%)
11.910 USD
TMO
TMO
3.25
(0.68%)
478.43 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.